CLIMB BIO INC (CLYM)
Health Care · Clinical-stage immunology / monoclonal antibody therapeutics · NASDAQ
Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and lupus.
What CLIMB BIO INC does
Climb Bio is a clinical-stage biotechnology company developing therapeutic candidates for immune-mediated diseases, with a focus on B-cell depletion strategies. The company's lead product, budoprutug, is an anti-CD19 monoclonal antibody in Phase 2 clinical trials for primary membranous nephropathy and Phase 1b/2a trials for immune thrombocytopenia. The company also has CLYM116, another product candidate, with development rights worldwide outside Greater China.
Themes: Immunology / immune-mediated diseases, B-cell depletion, Monoclonal antibodies, Autoimmune disease treatment, Clinical-stage biotech
Fundamentals
- Price$16.40 as of 2026-08-24 close
- Market cap$942M as of 2026-08-24
- 1-year return+589.1% 2025-08-22 close $2.38 → 2026-08-24 close $16.40
- P/En/a earnings data not available
- ROE-31.5% as of 2026-08-25
- Debt / equity0.00 as of 2026-08-25
- Beta-0.00 as of 2026-08-25
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CLYM compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-25
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CLIMB BIO INC looks technically
CLIMB BIO INC (CLYM) is trading 105.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 240 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 6 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 105.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +105.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.42 | $13.42 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.99 | $7.99 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 11.36. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 240 trading days ago — a "golden cross", a bullish long-term signal | 240 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with buyers in control | 43.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 64.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($12.14 to $18.14) — its "stochastic" reading is 71 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 71.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $18.14 | $18.14 |
|---|---|---|
| From the 52-week high | it is 9.6% below its 52-week high (its highest price of the past year) | -9.6% |
| Above the 52-week low | it is 964.9% above its 52-week low (its lowest price of the past year) | +964.9% |
| Below the 52-week high | it is 9.6% below its highest point of the past year | 9.6% |
| Since a 20-day breakout | it made a new 20-day high about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day high about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $29.69 (set on 2021-08-30) | $29.69 |
| Given back of the 52-week move | over the past year its closes ranged ($1.64 to $17.44), and it has given back only a small part of its rise from last year’s low — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.17 to $7.68. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 6.6% |
| From the all-time high | it is 44.8% below its all-time high | -44.8% |
| Nearest price level | it is trading 12.1% above a support level at $14.41 — a price it turned at twice since 2026-07-06, most recently on 2026-07-27. Since 2024-08-26 it has 12 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -12.1% |
| All-time low | its lowest closing price on record is $1.05 (set on 2025-04-07) | $1.05 |
| Above the all-time low | it is 1461.9% above its all-time low | +1,462% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months) | 98th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.11 between its high and its low — about 6.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.11 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $10.29 and $18.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $10.29 – $14.45 – $18.60 |
| Typical daily range (% of price) | its price moves about 6.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.7% |
| Stretch from the 200-day average | it is trading 7.6 daily ranges above its 200-day average price (105.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.04× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 5.9% since the prior reading | +5.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-24 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Open gap | it gapped 2.5% above the previous close 14 sessions ago and has not traded back through the level it left behind at 11.81 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.5% |
| Gap filled | a 4.0% gap up opened on 2026-08-19 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 24.4 percentage points (the stock gained 27.7% while the market gained 3.3%) | +24.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 46.7 percentage points (the stock gained 49.1% while the market gained 2.4%) | +46.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 146.8 percentage points (the stock gained 157.9% while the market gained 11.1%) | +146.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 570.8 percentage points (the stock gained 589.1% while the market gained 18.3%) | +570.8% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 28% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 10.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +27.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 56% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $10.49 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +56.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $15.83 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +3.6% |
Price levels it has turned at before
CLYM last closed at $16.40 on 2026-08-24. Since 2024-08-26 it has turned at 12 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $14.41 | Support | 12.1% below the last close | turned there twice · 2026-07-06 to 2026-07-27 |
| $6.22 | Support | 62.1% below the last close | turned there twice · 2026-02-13 to 2026-04-07 |
| $5.87 | Support | 64.2% below the last close | turned there twice · 2024-10-03 to 2026-03-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $11.36.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · Most volatile (6%+ typical daily range) · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.14 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$22.57 range $18.00 – $35.00; median $20.50
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CLYM
- Consensus EPS estimate-$0.1988 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no approved products or revenue; dependent on successful completion of Phase 2/Phase 1b trials for budoprutug in pMN, ITP, and SLE with uncertain regulatory approval outcomes","Significant ongoing losses with no current product revenue; substantial capital requirements to complete development and commercialization, with future financing needs and related dilution risks","Competitive landscape includes established players with approved B-cell targeting therapies and monoclonal antibodies; budoprutug must demonstrate superior efficacy, safety, or durability to gain market acceptance"]
What changed in the latest 10-Q
AI-assisted comparison of CLYM's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Form 10-K filed March 5, 2026 (for year ended December 31, 2025); older filing references Form 10-K filed March 25, 2025 (for year ended December 31, 2024)
- Newer filing states FDA granted FastTrack Designation for budoprutug in pMN in April 2026
- Newer filing describes budoprutug as designed to provide 'rapid, profound, and durable reductions in B cells and pathogenic autoantibodies'
- Newer filing states initial pMN data expected from low dose cohort at '12-24 weeks' in Q4 2026
- Newer filing states initial ITP data expected from low dose cohort at '24 weeks' in June 2026, with additional data by end of 2026
- Newer filing states ITP trial is 'open-label, dose-escalation Phase 1b/2a' (older describes same but with different phrasing)
- Newer filing states SLE trial received FDA clearance 'in October 2024' for 'Phase 1b clinical trial' and describes 'a single dose of budoprutug'
- Newer filing adds: 'In December 2025, we received clearance of our IND to initiate a separate, parallel Phase 1b/2a clinical trial in SLE patients in China' with expected first patient enrollment in Q2 2026 and potential lupus nephritis enrollment
- Newer filing states SC formulation Phase 1 trial initiated 'In September 2025' (older states 'In August 2025')
- Newer filing states SC formulation topline data announced May 2026 and was 'generally well-tolerated' with 'robust B-cell depletion, which was similar to the IV formulation at matched doses'
- Newer filing states plans to 'initiate a multiple dose study in autoimmune disease patients to evaluate full B-cell depleting doses and optimal dosing regimen' for SC formulation
- Newer filing describes CLYM116 as 'a highly potent, Fc-engineered antibody' with detailed mechanism: 'prevents APRIL signaling by potently blocking the binding of APRIL to its receptors and promoting lysosomal APRIL degradation through a pH-dependent bind-and-release sweeper mechanism'
- Newer filing states CLYM116 CTA clearance received 'In October 2025' in Australia and Phase 1 trial initiated
- Removed:
- Older filing language 'for the millions of patients' removed; newer states 'for patients' (simpler phrasing)
- Older filing reference to 'well-defined development paths and have the potential to address significant unmet needs' changed to 'well-defined development pathways, and the potential to address multiple indications' in newer
- Older filing's detailed description of three opportunity sets ('primarily IgG4-mediated diseases, primarily single organ IgG1-3 mediated diseases and complex systemic diseases') not present in newer filing
- Older filing's specific Phase 1b pMN trial data (60% complete remission, 3 of 5 patients, 48-week follow-up language) removed from newer filing
- Older filing's reference to October 2025 published long-term follow-up data from Phase 1b pMN trial removed from newer filing
- Older filing statement 'expect to dose our first patient in the coming weeks' for PrisMN removed; newer states trial is 'actively enrolling patients'
- Older filing's phrase 'Notably, the FDA has granted budoprutug orphan drug designation for the treatment of pMN' simplified in newer to include only in parenthetical reference with date added
- Older filing's reference to obtaining 'additional non-clinical data for the SC formulation in the first half of 2025' removed from newer
- Older filing's description of SC formulation demonstrating 'high bioavailability and favorable tolerability' removed from newer
- Older filing's statement 'We are actively enrolling and dosing subjects in this trial and expect to have initial clinical data in the first half of 2026' for SC formulation removed from newer
- Older filing's phrase 'together with the IV formulation, may provide the opportunity for a patient-tailored approach to treatment' not present in newer
- Reworded:
- Budoprutug description changed from 'which has the potential to address a broad range of B-cell mediated diseases' (older) to 'designed to deplete CD19-positive B cells... may allow for a disease-modifying therapeutic approach' (newer)
- Description of budoprutug mechanism changed from 'Budoprutug is designed to deplete CD19-positive B cells, including antibody secreting cells (plasma blasts), in order to directly reduce pathogenic autoantibodies' (older) to newer emphasizing 'CD19 plays a mechanistic role across all stages of B-cell development' and evidence supporting CD19 importance
- Initial development strategy phrasing: older states 'lead indications representing each of these three opportunity sets'; newer states focus on 'strong mechanistic rationale for CD19-directed therapy'
- SC formulation description changed from 'together with the IV formulation, may provide the opportunity for a patient-tailored approach' (older) to 'may offer a differentiated convenience profile and potential commercial advantage' (newer)
- Older trial description for ITP: 'Results from this trial are expected to provide a deeper understanding of budoprutug activity and dosing and will inform future development efforts in ITP and other immune-mediated diseases. We expect to have initial data, including preliminary efficacy, from the Phase 1b/2a clinical trial in ITP in the second half of 2026' changed to newer: specifying 'initial B-cell and platelet data from the low dose cohort (250 mg at 24 weeks)' with June 2026 expectation
- SLE trial data expectations changed from 'We expect to have initial data, including preliminary efficacy, from the Phase 1b clinical trial in SLE in the second half of 2026' (older) to 'We expect to have initial B-cell data from the global Phase 1b clinical trial in SLE in the fourth quarter of 2026' (newer)
- CLYM116 description expanded with detailed mechanism explanation in newer filing not present in older
- Notes:
- The newer MD&A text appears truncated at the end ('We initiated the Phase 1 clinical trial in hea'), limiting full assessment of CLYM116 section changes
- The older MD&A text also appears truncated ('In addition to budoprutug, we are also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) mAb for patients with immunoglobulin A nephropathy (Ig'), limiting full comparison of CLYM116 section
- Different fiscal year references (2024 vs 2025) in Form 10-K citations reflect normal quarterly progression rather than filing changes
Risk Factors
- Added:
- Newer filing mentions 'April 2026 private placement' and notes company is evaluating its impact on operating plan
- Newer filing states cash balance of $146.3 million as of March 31, 2026 (vs. $175.8 million as of September 30, 2025 in older filing)
- Newer filing adds language about 'excluding the gross proceeds received from the April 2026 private placement' regarding cash runway
- Newer filing updates accumulated deficit to $303.4 million as of March 31, 2026
- Newer filing updates net loss figures to $13.7 million for three months ended March 31, 2026 and $59.9 million for year ended December 31, 2025
- Newer filing changes cash runway guidance from 'through 2027' to 'into 2028' (before noting evaluation pending)
- Removed:
- Older filing contained standalone risk factor 'We may be required to make significant payments in connection with our license agreements' with detailed discussion of Asset Purchase Agreement, CRH Agreement, ProBioGen Agreement obligations - this section removed from newer filing
- Older filing's detailed list of bullet points about future capital needs included 'the timing, cost and progress of our research, preclinical, and clinical development activities' as first item - reordered in newer filing
- Older filing included 'establishing outsourced manufacturing relationships' language in opening paragraph of capital needs discussion - removed from newer filing
- Reworded:
- Title changed from 'We have incurred significant losses since our inception and anticipate that we will incur substantial losses' to 'We have incurred significant losses since our inception, expect to continue to incur substantial losses'
- Changed 'may never achieve or maintain profitability' to 'may never achieve or sustain profitability'
- Changed 'we do not expect to generate any revenue' to 'we do not expect to generate revenue from product sales'
- Reorganized list of capital need factors: older filing had narrative description followed by bullets; newer filing restructures with 'The' and different ordering of bullet points
- Changed 'preclinical studies and clinical trials, pursuing regulatory approvals, establishing outsourced manufacturing relationships and successfully manufacturing and commercializing' language to focus on 'nonclinical studies and clinical trials, obtaining regulatory approvals, and preparing for potential commercialization'
- Bullet point about tariffs changed from 'the imposition of tariffs an[d other trade restrictions]' to 'tariffs and other trade restrictions'
- Notes:
- Older filing text appears truncated at end; newer filing also appears truncated at end, limiting full comparison of complete sections
- Bullet point lists reorganized between filings, making direct comparison of specific ordering difficult
- Cash runway guidance in newer filing explicitly notes pending evaluation, making it conditional rather than firm
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($406979) — 1 selling insider
- Last 180 days0 buys · 1 sell ($406979) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-29. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CLYM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CLYM as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,103,009
- Reported value $7,555,611
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CLYM had 7,037,695 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CLYM had 12.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.75 days to cover at the same settlement.
- Reported short interest (shares) 7,037,695
- Short interest (% of shares outstanding) 12.3%
- Prior settlement (shares) 6,871,210
- Reported change 2.42%
- Days to cover (reported) 6.75
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche (RHHBY)
- Amgen (AMGN)
- Novartis (NVS)
- AstraZeneca (AZN)
- Bristol Myers Squibb (BMY)
- GSK (GSK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CLYM vs…
CLIMB BIO INC is found in…
CLYM ranks in…
Frequently asked questions
What does CLIMB BIO INC (CLYM) do?
Climb Bio is a clinical-stage biotechnology company developing therapeutic candidates for immune-mediated diseases, with a focus on B-cell depletion strategies. The company's lead product, budoprutug, is an anti-CD19 monoclonal antibody in Phase 2 clinical trials for primary membranous nephropathy and Phase 1b/2a trials for immune thrombocytopenia. The company also has CLYM116, another product candidate, with development rights worldwide outside Greater China.
What sector is CLIMB BIO INC (CLYM) in?
CLIMB BIO INC (CLYM) is classified in the Health Care sector. Its industry is Clinical-stage immunology / monoclonal antibody therapeutics. It trades on NASDAQ.
Who are CLIMB BIO INC's (CLYM) competitors?
Notable peers of CLIMB BIO INC (CLYM) include Roche, Amgen, Novartis, AstraZeneca and Bristol Myers Squibb. This peer set is informational only — not financial advice.
Is CLIMB BIO INC (CLYM) overbought or oversold right now?
CLIMB BIO INC (CLYM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CLYM come from?
Fundamentals and prices come from market data, as of 2026-08-25; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.